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Mast cells (MCs) are activated upon stimulation via TLRs or FceRI, contributing to immune protec-
tion and/or leading to allergic diseases. In the present study, the effects of Trichostatin A (TSA) on the
activation of MCs were analyzed with bone marrow-derived (BM) MCs. TSA increased the transcrip-
tion and protein secretion of IL-6 in case of LPS-stimulation, in contrast to the suppressive effect on
IgE-mediated activation of BMMCs. Chromatin immunoprecipitation assay showed IgE-mediated
signaling-speciﬁc suppression of transcription factors recruitment to the IL-6 promoter. TSA-
treatment inhibited nuclear translocation of NF-jB following IgE-mediated, but not LPS-induced
activation in MCs.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Trichostatin A (TSA), one of the most potent histone deacetylase
inhibitors (HDACi), belongs to the hydroxamic acids [1,2]. TSA and
another HDACi, suberoylanilide hydroxamic acid (SAHA), have also
been implicated in the manifestation of immunological diseases,
supposedly via regulation of the expression of several genes. For
instance, TSA was shown to reverse the aberrant expression of
cytokines in T cells from patients with systemic lupus erythemato-
sus (SLE) [3]. TSA and SAHA have been shown to be effective in
immune disease rodent models, including SLE [4,5], graft-versus-
host-disease [6], rheumatoid arthritis [7], and experimental
autoimmune encephalomyelitis [8]. In addition, there is a report
of therapeutic usage of TSA on allergic mouse model [9]. However,
the effects of TSA on the mast cells, a key element in immune
responses, have been rarely examined.
Mast cells (MCs) are activated upon stimulation by bacterial
components or by binding IgE to the high afﬁnity receptor, FceRI,
thereby contributing to immune protection or leading to allergicchemical Societies. Published by E
cell; ChIP, chromatin immu-
tyltransferase; HDAC, histone
MC, mast cell; PI, propidium
systemic lupus erythemato-
ama).disease. In brief, cross-linking of FceRI with IgE/allergen complex
causes immediate reaction including degranulation and the de
novo synthesis of eicosanoid, as well as delayed response with pro-
duction of proinﬂammatory cytokines such as IL-6 and TNF-a,
which are also released from LPS-stimulated MCs as innate immu-
nity. Therefore, it would be helpful to ﬁnd reagents that selectively
regulate speciﬁc functions of MCs for provide new therapeutic ap-
proach for MC-mediated diseases.2. Materials and methods
2.1. Preparation of bone marrow-derived mast cells (BMMCs)
Mouse BMMCs were prepared as described previously [10–12]
with over 95% of purity.
2.2. Quantitative real-time PCR
After treatment with TSA (from Streptomyces sp.; Sigma),
BMMCs were stimulated with either IgE/anti-IgE or LPS for 1 h at
37 C as described previously [11,13,14]. Extraction of total RNA
and cDNA synthesis with RT reaction was performed as described
previously [15]. Quantitative real-time PCR to determine the
mRNA level of IL-6 (Mm00446190_ml) was performed as described
previously [16].lsevier B.V. All rights reserved.
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After incubation with TSA, BMMCs at concentration of 1  106/
ml were stimulated with either IgE/anti-IgE or LPS for 6 h at 37 C.
The concentration of IL-6 in culture supernatant was determined
by an ELISA kit according to the manufacturer’s instructions
(R&D Systems, Minneapolis, MN).
2.4. Chromatin immunoprecipitation (ChIP) assay
A ChIP assay was performed as previously described [12,17,18].
Anti-NF-jB p65 rabbit IgG (C-20; Santa Cruz Biotechnology, CA),
anti-c-Jun rabbit IgG (D; Santa Cruz Biotechnology), anti-acetyl-
histone H4 rabbit antiserum (Upstate, Lake Placid, NY), and rabbit
IgG (Invitrogen) were used. Quantitative PCR was performed with
the following primer and TaqMan probe: for the mouse IL-6
promoter (84/9), forward primer IL-6-84F (50-CCCATGAGTCT-
CAAAATTAGAGAGTTG-30), reverse primer IL-6-9R (50-CAGA-
GCAGAATGAGCTACAGACATC-30), and TaqMan probe IL-6-56P
(50-CTCCTAATAAATATGAGACTGGG-30) as described previously [17].
2.5. Statistical analysis
Statistical analysis was performed using the two-tailed paired
Student’s t-test. Data are presented as means ± S.D. A P value less
than 0.05 was considered statistically signiﬁcant.
2.6. Immunoﬂuorescence
BMMCs, which were preincubated with 10 nM TSA for 24 h,
were stimulated with IgE/anti-IgE or LPS for 30 min. After washing
with cold PBS, the cells were cytocentrifuged with a Cytospin 4
centrifuge (Thermo Shandon) at 800 rpm for 5 min, and ﬁxed in
4% paraformaldehyde for 10 min, and then the ﬁxed cells were per-
meabilized with 0.1% Triton X-100-PBS for 3 min. After treatment
with goat IgG (10 lg/ml) in 1% BSA-PBS for 30 min to block non-
speciﬁc binding, the cells were incubated with 10 lg/ml rabbit
anti-p65 Ab (C-20) for 1 h followed by incubation with 1 lg/ml
goat anti-rabbit IgG conjugated with Alexa Fluor-488 (Molecular
Probes) for 30 min. All procedures after cytospin were performed
at room temperature. Nuclei were counterstained with propidium
iodide. Fluorescence images were acquired with a Zeiss ﬂuores-
cence microscope and analyzed with AxioVision software (Carl
Zeiss).
2.7. Subcellular fractionation and immunoblotting
BMMCs,whichwere preincubatedwith 10 nMTSA for 24 h,were
stimulatedwith IgE/anti-IgE for 30 min. The cytoplasmic and nucle-
ar fractions were isolated from the cells by a subcellular fraction kit
according to the manufacturer’s instructions (ProteoExtract, Merck,
Darmstadt, Germany). Equal amounts of proteins (1.2 lg) fromeach
fraction were subjected to SDS–PAGE and transferred onto polyvi-
nylidine diﬂuoride members (Millipore). The membrane was incu-
bated with rabbit anti-p65 Ab (C-20) followed by anti-rabbit IgG
conjugated with Alexa Fluor-680 (Molecular Probes). Infrared ﬂuo-
rescence on themembranewas detectedby an infrared imaging sys-
tem Odyssey (LI-COR Biosciences, Lincoln, NE).0 2 10
0
TSA (nM)
Fig. 1. Effects of TSA on FceRI-mediated BMMC activation. (A) IL-6 mRNA level in
BMMCs. (B) IL-6 secreted from BMMCs. Data represent the average ± S.D. of
triplicate samples. Representative results of two or three independent experiments
are shown in Figs. 1 and 2. **P < 0.01 and ***P < 0.005.3. Results
3.1. Suppressive effect of TSA on FceRI-mediated BMMC activation
We determined the degree of IL-6 production from TSA-pre-
treated BMMCs following FceRI cross-linking to evaluate the effectof TSA on IgE-mediated activation. Transcript expression of IL-6
was dose-dependently reduced in cells preincubated with TSA
(Fig. 1A), consistently reﬂected in signiﬁcantly decreased secretion
of IL-6 protein (Fig. 1B). These data indicate that TSA suppressed
FceRI-mediated BMMC activation dose-dependently.
3.2. The effect of TSA on the production of IL-6 from BMMC upon
LPS-stimulation
To examine whether the suppressive effect of TSA on MCs is
prevalent, we detected the IL-6 production from BMMCs stimu-
lated by LPS. Interestingly, pretreatment of BMMC with 2 nM or
10 nM TSA substantially augmented IL-6 transcript induction by
LPS (Fig. 2A) and elevated IL-6 protein secretion upon LPS-stimula-
tion (Fig. 2B). These results indicate that TSA has a transactivating
effect on IL-6 production from BMMCs in response to LPS-
stimulation.
3.3. TSA suppresses FceRI-mediated activation of NF-jB and AP-1
Activation of transcription factors, NF-jB and AP-1, are induced
by FceRI-mediated signal cascades and result in IL-6 transcription
in MCs [19,20]. Recently, HDACi were found to affect the activity
of NF-jB by promoting the acetylation [21]. Then, to evaluate the
effect of TSA on activation of these transcription factors, ChIP assay
was performed. FceRI cross-linking increased the amount of p65
binding to the IL-6 promoter, and the increase was suppressed
by TSA-treatment, whereas p65 recruitment to the IL-6 promoter
in LPS-stimulated BMMCs was not affected by TSA (Fig. 3A).
Recruitment of c-jun, which was observed in FceRI-stimulated
BMMCs but not in the case of LPS-stimulation, was reduced in
TSA-treated BMMCs (Fig. 3B). These results indicate that TSA sup-
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Fig. 2. Effects of TSA on LPS-induced BMMC activation. (A) IL-6 mRNA level in
BMMCs. (B) IL-6 secreted from BMMCs. **P < 0.01 and ***P < 0.005.
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Fig. 3. Statement of histone acetylation and transcription factor binding on the IL-6
promoter region in TSA-treated BMMCs upon stimulation. TSA suppresses FceRI-
mediated recruitments of NF-jB (A) and AP-1 (B) to the IL-6 promoter. Quantitative
ChIP analysis of binding between the IL-6 promoter and NF-jB p65 (A), or c-jun (B).
BMMCs were pretreated with 10 nM of TSA for 24 h at 37 C. Statement of histone
acetylation analyzed by quantitative ChIP assay of acetylated histones H4 binding
to the IL-6 promoter in BMMC upon stimulation by LPS (C) or IgE (D). A result from
three independent ChIPs is shown. E, IgE/FceRI cross-linking; L, LPS-stimulation.
Closed bars, speciﬁc Ab; open bars, control Ab. *P < 0.05 and ***P < 0.005.
Q.-h. Wang et al. / FEBS Letters 584 (2010) 2315–2320 2317presses FceRI-mediated recruitment of transcription factors to-
ward the promoter without affecting LPS-mediated recruitment.
3.4. TSA induces accumulation of acetylated histones on the mouse
IL-6 promoter in BMMCs
In order to conﬁrm that the effect of TSA on the IL-6 promoter is
a modulator of histone acetylation state, we performed a ChIP as-
say to examine the amount of acetylated H4 (Fig. 3C and D) and H3
(data not shown) on the promoter region of IL-6 within TSA-trea-
ted BMMCs upon stimulation. The amount of promoter region of
IL-6 immunoprecipitated with anti-acetylated H4 Ab was signiﬁ-
cantly higher than that with each control Ab in LPS- and IgE-stim-
ulated BMMCs (0 nM TSA in Fig. 3C and D), indicating that histones
H4 on the IL-6 promoter are highly acetylated in activated mast
cells. In addition, pretreatment of BMMCs with the indicated con-
centration of TSA resulted in increased amounts of IL-6 promoter
region bound with acetylated H4 with stimulation independent
manner (Fig. 3C and D). Similar results were also obtained from
ChIP assay using anti-histone H3 Ab with TSA-treated BMMCs
(data not shown). These data suggest that the status of histone
acetylation on the IL-6 promoter, which is induced by TSA is asso-
ciated with the enhanced transcription of IL-6 under LPS-stimula-
tion, whereas the increased histone acetylation is not reﬂected in
the suppression of FceRI-mediated reaction by TSA.
3.5. TSA inhibits FceRI-mediated nuclear translocation of NF-jB
ChIP assay demonstrated that TSA suppressed the binding of
transcription factors, NF-jB and c-jun, against the IL-6 promoter,
which was induced by FceRI-stimulation. To further evaluate the
effect of TSA on NF-jB function, localization of NF-jB p65 subunit
Fig. 4. TSA-treatment suppresses IgE-dependent nuclear translocation of NF-jB. (A) Subcellular localization of the NF-jB p65 subunit in BMMCs as determined by
immunocytochemistry and microscopy. Left panels, anti-NF-jB p65/RelA staining (green); middle panels, nucleus by propidium iodide staining (red); right panels, merged
images. Scales mean 10 lm. (B) Protein levels of p65 in each fraction were analyzed by immunoblotting with anti-NF-jB p65/RelA Ab. C, cytoplasm; N, nucleus.
2318 Q.-h. Wang et al. / FEBS Letters 584 (2010) 2315–2320in TSA-treated BMMCs was determined by immunocytochemistry
and microscopy. Stimulation of BMMCs with LPS or IgE/anti-IgE re-
sulted in the translocation of the cellular p65 into the nucleus in
the absence of TSA (Fig. 4A top three panels). When BMMCs were
preincubated with TSA, FceRI-mediated nuclear translocation of
the p65 was prevented, whereas LPS-mediated nuclear transloca-
tion was still observed in the presence of TSA (Fig. 4A bottom three
panels). Translocation of p65 protein was also analyzed by westernblotting with fraction of cytoplasm and nuclear (Fig. 4B). The
immunoblotting study showed that p65 proteins, which localized
in cytoplasm in non-stimulated BMMCs (0 min), partly translo-
cated to nuclear at 30 min after FceRI cross-linking. The band
intensity of nucleus p65 of stimulated BMMCs was reduced by
TSA-pretreatment. These results suggest that TSA inhibits a step
in NF-jB activation at or prior to nuclear translocation in an
FceRI-signaling speciﬁc manner.
Q.-h. Wang et al. / FEBS Letters 584 (2010) 2315–2320 23194. Discussion
When we analyzed the expression levels of other cytokines,
including IL-13 and TNF-a, TSA exhibited similar effects as those
on IL-6 expression; in brief, suppression of IgE-mediated activation
and enhancement of LPS-mediated activation (data not shown).
These observations indicate that these TSA effects are targeting
the molecules related to an IgE- and LPS-dependent signaling path-
way, and commonly affecting the cytokine promoters.
The HDACi including TSA positively [3,22,23], negatively [4], or
non-effectively [24] regulate cytokine genes in various immunore-
lated diseases. Furthermore, the effect of TSA on LPS-stimulated
MC in the present study is distinct from previously reported these
effects of SAHA and LAQ824 on LPS-induced gene expression from
mesangial cells [5] and dendritic cells [25]. Further study compar-
ing the effects of each HDACi on gene regulation in various cells
will be required to clarify the mechanism causing the complicated
observations.
HDACi enhances acetylation of p50 and p65 of NF-jB [21],
resulting in suppression [26] or promotion [27] of NF-jB activa-
tion. In many cases, HDACi suppresses proinﬂammatory cytokine
production induced by activated NF-jB [28,29]. HDACi inhibits
LPS-induced NF-jB activation in DCs [30], endothelial cells and
monocytes [31]. Although it is not revealed the mechanism that
p65/RelA recruitment in response to LPS-stimulation in MCs was
not suppressed by TSA, TSA sensitivity may cause this difference,
as TSA does not diminish p65/p50 binding to the NF-jB element,
whereas TSA abolishes p65/c-Rel binding to TF-jB element [31].
Further detailed analysis including detection of NF-jB acetylation
status will be required for clarify these issue. TSA-pretreatment in-
creases the acetylation status of histones H3 and H4 on the IL-6
promoter (Fig. 3C and D, and data not shown). This may be one
of the mechanisms of upregulation of LPS-induced transactivation.
Brieﬂy, enhanced histone acetylation by TSA may accelerate IL-6
transactivation upon LPS-stimulation. In contrast, because NF-jB
activation itself and/or its upstream events of FceRI-mediated sig-
naling are inhibited by TSA (Fig. 4), the increased acetylation of
histones may not be reﬂected in the gene expression in FceRI-stim-
ulated MCs. We speculate that opposite effects of TSA, in brief, IgE-
mediated signaling-speciﬁc suppression and LPS-induced signaling
enhancement, are due to various effects of TSA targeting several
molecules including those regulating IgE-mediated signal trans-
duction and histone acetylation.
Quite recently, a study regarding an analysis of HDACi effects on
MC activation was reported [32]. In that report, an HDACi
MGCD0103 inhibited histamine release from FceRI cross-linked
rat peritoneal MCs, but SAHA and diamide 1 did not inhibit. In
the present study, we found that FceRI-mediated degranulation
was inhibited by TSA (data not shown). Considering the different
effect of various HDACi on MC degranulation, effects of other
HDACi including TSA should be analyzed to clarify the inhibition
mechanisms of each HDACi and to identify and/or design the
HDACi suitable for regulation of MC-function.
Our present study also demonstrates that MCs are sensitive to
the effects of TSA at nanomolar concentration. Considering the rare
side-effects observed in vivo experiments [4–9], TSA is a poten-
tially safe agent to attenuate the development of allergic diseases
via its suppressive effect on the IgE-mediated activation of MCs.
Meanwhile, the ability of MCs against bacterial infection would
not be affected or even strengthened by the application of low
doses of TSA. In our preliminary experiment, TSA-pretreatment of
mice suppressed the passive cutaneous anaphylaxis reactions in
a dose-dependent manner (data not shown), suggesting that TSA
inhibits MC-dependent immediate hypersensitivity reactions in
vivo. Regardless, further detailed analyses to clarify target mole-cules of TSA in MCs will be required for revealing the regulation
mechanism of the MC-function by TSA.
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